Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
This diversified healthcare company is a new holding (owned previously in the 2010s) and is off to a strong start for us. In the first...
— Ross Glotzbach
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Abbott Laboratories
Abbott Laboratories ($ABT) makes up 3.4% of the fund's capital. As a diversified...
Abbott Laboratories is a diversified global healthcare company operating across medical devices, diagnostics, branded generic pharmaceuticals, and nutritional products. Abbott represents 5.0%...
At the end of the day, it was always something with Abbott.
More institutional theses from Longleaf Partners Global Fund
Rayonier ($RYN), representing 7.2% of the fund's portfolio, is a leading real estate investment trust specializing in timberland management, real estate development, and natural resource conservation across the United States and New Zealand. The manager maintains...
Regeneron Pharmaceuticals ($REGN), representing 4.7% of the fund's portfolio, is a leading biotechnology company that discovers, invents, and commercializes innovative medicines for serious diseases. The manager maintains...
Fortune Brands Innovations ($FBIN) is a leading manufacturer of home and building products, focusing on water innovations, outdoor living, and home security. The manager trimmed...